Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Euronext Paris  >  Ipsen    IPN   FR0010259150

IPSEN

(IPN)
  Report  
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsOfficial PublicationsSector newsMarketScreener StrategiesAnalyst Recommendations

Ipsen : Back on the support level

share with twitter share with LinkedIn share with facebook
share via e-mail
08/23/2019 | 04:15am EDT
long trade
Stop-loss triggered
Entry price : 94.3€ | Target : 103.7€ | Stop-loss : 89.8€ | Potential : 9.97%
The Ipsen share is coming back to a technical support zone comprising the lower bound of the trading range. This provides a good timing to go long on the stock.
Investors have an opportunity to buy the stock and target the € 103.7.
Chart IPSEN
Duration : Period :
Ipsen Technical Analysis Chart | MarketScreener
Full-screen chart
Summary
  • The company has strong fundamentals. More than 70% of listed companies have a lower mix of growth, profitability, debt and visibility criteria.

Strengths
  • The current area is a good opportunity for investors interested in buying the stock in a mid or long-term perspective. Indeed, the share is moving closer to its lower bound at EUR 92 EUR in weekly data.
  • The close medium term support offers good timing for purchasing the stock.
  • Margins returned by the company are among the highest on the stock exchange list. Its core activity clears big profits.
  • The company is in a robust financial situation considering its net cash and margin position.
  • Over the last twelve months, the sales forecast has been frequently revised upwards.
  • Analysts covering this company mostly recommend stock overweighting or purchase.
  • The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.

Weaknesses
  • With an enterprise value anticipated at 3.34 times the sales for the current fiscal year, the company turns out to be overvalued.
  • The firm pays small or no dividend to shareholders. For that reason, it is not a yield company.
  • For the last few months, analysts have been revising downwards their earnings forecast.
  • The technical configuration over the long term remains negative on the weekly chart below the resistance level at 120 EUR
Ipsen : Back on the support level

Jordan Dufee
© Zonebourse.com 2019
share with twitter share with LinkedIn share with facebook
share via e-mail

Disclaimer: The information, charts, data, views, or comments provided by SURPERFORMANCE SAS are intended for investors who have the necessary knowledge and experience to understand and appreciate the information contained within. These items are disseminated for personal reference only. They do not constitute an offer or solicitation to buy or sell financial products or services, nor an investment advice.
The use of the information disseminated takes place under the investor's sole responsibility, without recourse against SURPERFORMANCE SAS. SURPERFORMANCE SAS will not be liable, whether in contract, in tort, under any warranty, for errors, omissions, improper investments, or adverse evolution of markets.

Financials (EUR)
Sales 2019 2 592 M
EBIT 2019 744 M
Net income 2019 482 M
Debt 2019 978 M
Yield 2019 1,19%
P/E ratio 2019 15,9x
P/E ratio 2020 13,4x
EV / Sales2019 3,36x
EV / Sales2020 2,84x
Capitalization 7 718 M
Upcoming event on IPSEN
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 16
Average target price 127,84  €
Last Close Price 92,95  €
Spread / Highest target 52,8%
Spread / Average Target 37,5%
Spread / Lowest Target 10,8%
EPS Revisions
Managers
NameTitle
David D. Meek Chief Executive Officer & Director
Marc M. P. de Garidel Non-Executive Chairman
Aymeric Le Chatelier Chief Financial Officer & Executive Vice President
Alexandre P. LeBeaut Chief Scientific Officer
Sotirios G. Stergiopoulos Chief Medical Officer
Sector and Competitors
1st jan.Capitalization (M$)
IPSEN-17.63%8 533
JOHNSON & JOHNSON0.38%342 221
ROCHE HOLDING LTD.14.65%240 139
MERCK AND COMPANY7.98%211 257
PFIZER-16.38%201 883
NOVARTIS15.63%198 222